cat no | io1002
ioSkeletal Myocytes, are human iPSC-derived skeletal myocytes precision reprogrammed using opti-ox™ technology. Skeletal myocytes are delivered cryopreserved, upon revival the cells rapidly mature forming elongated striated, multinucleated muscle cells that contract within 10 days. Easy to culture, skeletal myocytes consistently exhibit high population purity expressing key myofilament proteins such as Desmin and Myosin Heavy Chain (MHC).
ioSkeletal Myocytes provide a source of highly-defined, consistent and reliable human muscle cells for research, disease modelling and high-throughput screening across areas such as muscle, neuromuscular, and associated metabolic disorders.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Consistent
Batch-to-batch reproducibility and homogeneity create a stable human model for the study of muscle, neuromuscular, and associated metabolic disorders.
Quick
Form striated, multinucleated, myocytes by day 10 post revival, that contract in response to acetylcholine.
Easy-to-use
Cells arrive programmed to rapidly mature upon revival. One medium is required in a two-step protocol.
ioSkeletal Myocytes generated by transcription factor-driven reprogramming of iPSCs using opti-ox technology
ioSkeletal Myocytes express skeletal myocyte-specific markers
Cells demonstrate classical myocyte morphology
Cells demonstrate gene expression of key myogenic markers following reprogramming
Cells are suitable for phenotypic based high-throughput screening
Cells express the insulin regulated glucose transporter GLUT4, critical for metabolic studies
Available in two vial sizes, tailored to suit your experimental needs with minimal waste
Dr Marieke Aarts | Principal Scientist | Bi/ond
Amanda Turner | Senior Product Manager | bit.bio
Dr Mitchell Han
Bi/ond
2023
Rochford and Carnicer-Lombarte et al.
Science Advances
2023
Oosterveen et al
bit.bio
2022
Dr Will Bernard | Director of Cell Type Development | bit.bio
Dr Luke Flatt | Senior Scientist | Charles River Laboratories
Dr Will Bernard | Senior Scientist | bit.bio
Bernard, et al
bit.bio
2021
Read this blog to find out how our precision cellular reprogramming technology, opti-ox is powering cell identity, giving you easy access to endless and reliable human cells!